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Abstract
Milk contains many types of proteins, which are classifi ed into two general categories – caseins and whey 
proteins. Due to their nutritional and functional properties, milk protein products are widely used in the 
food industry. This entry summarizes the current knowledge on milk protein fractions and their biological 
properties. The production of the main protein-enriched products is described. In addition, an overview of 
the current and potential biomedical applications of milk proteins is given.
 INTRODUCTION
Milk proteins are usually classifi ed into two major catego-
ries: the caseins (CNs), which coagulate or precipitate at 
pH 4.6, and the serum (whey) proteins that remain in solu-
tion at pH 4.6. Because of their high nutritional quality and 
versatile functional properties, milk proteins are widely 
used as ingredients in many manufactured foods. More 
recently, milk proteins have been used for drug delivery 
and tissue engineering applications.
This entry starts by presenting the bovine milk protein 
system followed by an overview of the methods for the 
commercial production of the main milk protein-enriched 
products. Information on the reported health effects attrib-
uted to milk proteins is also given. The entry ends by sum-
marizing the latest research on milk proteins’ biomedical 
applications.
MILK COMPOSITION
The major constituents of milk are water (87.1%), lactose 
(4.6%), fat (4.0%), protein (3.3%), minerals (0.7%), 
organic acids (0.17%), and a small number of other con-
stituents present only in trace amounts, e.g., vitamins and 
enzymes (0.15%). Bovine milk contains about 3.3% milk 
proteins, discounting non-protein nitrogen, e.g., urea, 
ammonia, and free amino acids. Around 80% of the total 
amount of proteins are CNs; the remaining 20% are referred 
to as whey proteins or milk serum proteins.[1]
Milk Proteins (Lactoproteins)
Proteins present in milk are divided into CNs and whey pro-
teins, which are separated by milk acidifi cation to pH 4.6.
Caseins
Caseins are defi ned chemically as the milk proteins that 
precipitate at pH 4.6, which are found in milk and syn-
thesized in mammary glands in response to the hormone 
prolactin.[2] Caseins express an extraordinary degree of 
heterogeneity, involving several proteins that diverge 
substantially in composition and functions.[3] By separat-
ing fragments by electrophoresis, it is possible to deter-
mine α, β, κ, and γ-CN (α-CN, β-CN, κ-CN, and γ-CN). 
γ-CN is a proteolytic product obtained after cleavage of 
β-CN by plasmin. The CN products are discriminated 
based on their electrophoretic properties and the capacity 
to precipitate in the presence of calcium, at a concentra-
tion of 6 mM and at a temperature of 20°C, into the 
 calcium-sensitive α- and β-CN on one hand and the 
insensitive κ-CN on the other hand. As milk contains 
roughly 30 mmol/L Ca, it would be expected that most of 
the CNs would precipitate in milk. However, κ-CN is 
soluble at high concentrations of Ca, and it reacts with 
and stabilizes the Ca-sensitive CNs through the forma-
tion of CN micelles.[2–4]
The bovine CN group comprehends four individual 
gene products known as αS1-CN, αS2-CN, β-CN, and κ-CN 
in estimated proportions of 4:1:4:1 (w/w). Each of the focal 
CN components displays additional variability due to dif-
ferent degrees of phosphorylation, glycosylation, disulfi de 
bonding, proteolysis, and genetic polymorphism.[4] Caseins 
have a relatively high proline content and consequently 
very little secondary or tertiary structure that can be dena-
tured. Yet, at temperatures higher than 140°C, CNs heat 
coagulate either by colloidal aggregation or by chemical 
cross-linking. The colloidal aggregation involves calcium 
bridges, depending on temperature, calcium concentration, 
and pH.[1]
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The low content of α-helical structure makes the CNs to 
be open and fl exible, enabling the accessibility for the pro-
teolytic enzymes to the CN molecules and making them 
easy to degrade. The CNs are capable of associating with 
each other or self-association, depending on pH, ionic 
strength, and temperature. Depending on the quantity of 
phosphoserine residues in the molecule, the different CN 
components indicate diverse calcium-binding abilities. 
κ-CN has a very low, if any, calcium-binding capacity with 
only one phosphoserine, while αS1-CN, αS2-CN, and β-CN, with several phosphoserines, have high binding 
capacities. About 95% of the CNs in bovine milk are incor-
porated into large colloidal structures: micelles. These 
structures are not still entirely understood; however, vari-
ous models have been proposed. The most denoted and 
debated models are “the submicelle model,” “the hairy 
model,” and the “dual binding model.” The proposed CN 
micelle models have two important aspects in common: the 
inclusion of calcium phosphate and the κ-CN rich surface. 
It has been proposed that the CNs are organized into tubu-
lar substructures with gaps in between and that κ-CN is 
grouped at the end of these tubules, on the outer part of the 
micelle.[3–6]
All major milk proteins have dissimilar genetic variants. 
Genetic polymorphism of milk proteins arises when amino 
acids are either substituted in or deleted from the amino 
acid chain. These alterations are the consequence of muta-
tions causing changes in the gene base sequences. The 
detected genetic variants of CN proteins are: αS1-CN A, B, 
C, D, E, F, G, H; αS2-CN A, B, C, D; β-CN A1, A2, A3, B, 
C, D, E, F,G; and κ-CN A, B, C, E, FS, FI, GS, GE, H, I, J.[7]
Milk whey proteins
The amount of whey proteins is approximately 20% of the 
total milk proteins. These proteins are chemically charac-
terized by being soluble at pH 4.6. The acid whey contains 
lactalbumins, soluble in 50% saturated (NH4)2SO4 or satu-
rated MgSO4, and lactoglobulins. The two major proteins 
are β-lactoglobulin (β-Lg) and α-lactalbumin (α-La), and 
also some minor proteins (including blood serum albumin 
and lactoferrin (LF)).
Compared to CNs, whey proteins have a more ordered 
secondary and tertiary structure and are usually globular 
proteins. They are also more heat sensitive, with initiation 
of denaturation/unfolding at temperatures around 60°C, 
more hydrophilic, and the majority contains high amounts 
of α-helical structure.[2]
β-Lactoglobulin: β-Lg represents approximately 50% 
of the whey proteins (∼12% total proteins) and contains 
162 amino acid residues, with a molecular weight of 18 
kDa. It has six cysteine residues, resulting in two disulfi de 
linkages and one very reactive free sulfhydryl group, which 
in the native state is hidden within the molecule. It is a 
typical globular protein, and at pH range 5.5–7.5, it exists 
as a dimer of two monomeric subunits. After decreasing 
pH to below 5.5, a tetramer is molded, though the protein 
occurs as a monomer at pH below 3.5. The β-Lg structure 
has an eight-stranded antiparallel β-barrel establishing the 
molecular core. Most likely, β-Lg realizes a biological role 
by transporting vitamin A to the small intestine. By binding 
many hydrophobic molecules its ability to bind retinol may 
be incidental.[4,8]
α-Lactalbumin: α-La represents approximately 20% of 
the whey proteins (∼3.5% total proteins). It has a molecular 
weight of nearly 14 kDa and consists of a single polypep-
tide chain of 123 amino acids. It comprises four tryptophan 
residues, one larger subdomain with three α-helixes, and 
one smaller subdomain containing a three-stranded anti-
parallel β-sheet.[4] It is a component of lactose synthetase, 
the enzyme involved in the biosynthesis of lactose. There-
fore, it has an essential biological function in the synthesis 
of lactose from UDP-D-galactose and D-glucose. The con-
centration of lactose in milk is directly linked to the 
 concentration of α-La.[9]
Whey proteins of bovine milk all exhibit genetic poly-
morphism. Among them,  β-Lgs are the most important 
and highly studied protein genes and, at least, 11 variants 
are known for β-Lg, of which, A and B variants are the 
most common:  β-Lg A, B, C, D, E, F, H, I, J and α-La A, 
B, C.[10] There are more whey milk proteins, but are present 
in very low quantities including serum albumin (also 
named lactalbumin and milk albuminate), immunoglobu-
lins (IgG, IgA, and IgM), and the proteins of the milk fat 
globule membrane.[11]
Milk contains roughly 60 indigenous enzymes, which 
epitomize a minor but vital part of the milk protein system. 
Some examples are: alanine aminotransferase, catalase, 
peroxidase, acid and alkaline phosphatases, and protease.[12]
Some specifi c chemical properties of bovine’s milk 
CNs, α-Lg, and β-Lg are listed in Table 1.
MILK PROTEIN PRODUCTS
There are several milk protein products, e.g., CNs, casein-
ates, and different whey proteins, which are manufactured 
from milk by the dairy industry. Milk protein hydrolysates 
and derived bioactive peptides have arisen as potential 
ingredients for application in food and mostly in nutraceu-
tical formulations.
The described products are a vast assortment of what is 
extensively used in biotechnological, biomedical, pharma-
ceutical, and food industries and research. Both the manu-
facturing process and applications will be described.
Caseins and Caseinates
Casein is manufactured from skim milk by one of two 
methods: precipitation by acid or coagulation by proteo-
lytic enzymes. Fat, whey proteins, lactose, and minerals 
must be removed from the CN by washing in water to 
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improve the quality of the fi nal CN product. The product is 
dried to improve conservation and is used mainly in the 
food and chemical industries.
In the production of acid CN, the milk pH is decreased 
to approximately pH 4.6, corresponding to the isoelectric 
point of CNs. Such acidifi cation can be carried out biologi-
cally (by lactic acid bacteria) or by addition of a mineral 
acid (usually hydrochloric or sulfuric acid) yielding lactic 
acid CN and mineral CN, respectively (Fig. 1). Rennet CN 
results from the enzymatic precipitation carried out by sev-
eral proteolytic enzyme preparations (typically rennet).
Micellar CN, generally referred to as phosphocaseinate, 
has similar compositional and physical characteristics to 
the native CN micelles in milk. Micellar CN is manufac-
tured by microfi ltration of fresh skim milk using a mem-
brane of suitable pore size, which allows permeation of the 
serum proteins and soluble constituents whilst retaining the 
CN micelles. Any soluble permeable constituents are fur-
ther removed by diafi ltration with water and the retained 
solution is usually spray dried.
Caseinates can be produced from freshly precipitated 
acid CN curd or from dry acid CN by reaction with a dilute 
alkali solution. The most commonly used alkali is sodium 
hydroxide but others like potassium hydroxide, calcium 
hydroxide, or ammonia can also be used. Caseinates 
are usually salts of sodium or calcium and have a pH of 
6.5–7.0. These products are soluble in water.
Fractionation of caseins
Fractionation of CNs may be needed for a number of 
 reasons, for instance, β-CN is an interesting ingredient 
for infant formulae, as human milk does not contain it, 
and κ-CN can be applied as a stabilizer in certain milk 
products.[15] Most important, the use of individual CN frac-
tions is a condition for the generation and recovery of CN-
derived bioactive peptides of high purity. Chromatographic 
methods can be used to fractionate CNs and have been 
shown to be better than precipitation procedures[16] but are 
unsuitable for producing CN for human consumption, due 
to the utilization of non-food grade reducing agents such as 
dithiothreitol or β-mercaptoethanol. This issue can be sur-
passed by using microfi ltration of skim milk tailed by 
anion exchange chromatography using L-cysteine as a 
food grade reducing agent in the eluting buffer.[17] Table 2 
summarizes the nutritional and pharmaceutical use of CNs 
and their products.
Whey Protein-Enriched Products
Whey is the serum or liquid remaining after the removal of 
fat and CN from milk during the manufacture of cheese or 
acid and rennet CN. It contains whey proteins, lactose, 
minerals, and a small amount of fat. Whey as a by-product 
of the manufacturing process of cheese and rennet CN is 
known as sweet whey and has a pH of 5.9–6.6. Manufac-
ture of mineral-acid-precipitated CN yields acid whey with 
a pH of 4.3–4.6. Table 3 shows the main differences 
between sweet and acid whey.
Whey and whey protein-enriched solutions are usually 
pasteurized using minimum temperature and holding times 
and maintained at low temperature to minimize microbial 
spoilage and physico-chemical deterioration of the pro-
teins and other constituents that would affect the functional 
and organoleptic properties of the end products.
Table 1 Particular chemical properties of bovine’s milk caseins, α-lactalbumin (α-La), and β-lactoglobulin (β-Lg)
Protein α
s1-CN αs2-CN β-CN κ-CN α-La β-Lg
Concentration (g/L) 12–15 3–4 9–11 2–4 0.6–1.7 2–4
Phosphorylated 9 9 9 9 8 8
Molecular weight 23,542–23,615 25,226 23,983–24,092 19,006–19,037 14,178 18,277–18,363
Isoelectric point 4.44–4.76 4.44–4.76 4.83–5.07 5.3–5.8 4.2–4.5 5.13
Solubility at pH ~4.6 Insoluble Soluble
Heat stability Very heat stable: tolerate heat at 140°C – 20–25 min Entirely denatured at 90°C – 10 min
Physical state in milk Large colloidal aggregates as micelles Monomers or small quaternary structures
Source: Data adapted from Walstra et al.,[1] Gonçalves Ferreira,[12] Fox & McSweeney[13] and Farrell et al.[14]
Fig. 1 Production of casein-enriched products.
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exceeds 90%, the product is known as WPI. WPI is pro-
duced from whey by ion-exchange chromatographic meth-
ods and usually contains 90–95% protein.
In Table 4 are summarized whey protein products’ 
applications in the food and pharmaceutical industries.
Fractionation of whey proteins
For some applications selected isolated proteins may be 
desirable. For instance, for preparation of infant formulae 
α-La appears to be more appropriate since β-Lg is the most 
allergenic of the bovine milk proteins to the human infant (in 
fact human milk does not contain β-Lg), justifying in this 
way the commercial interest for fractionating α-La and β-Lg.
Table 2 Casein-enriched products and their nutritional and pharmaceutical use
Type of casein
Caseins in 
general
α-Casein/rennet 
casein β-Casein κ-Casein Sodium caseinate
Phosphocaseinate 
(micellar casein)
Applications Water dispersible 
protein
Special dietary 
foodstuffs
Toothpaste
Special dietary 
foodstuffs
Infant formulae Stabilizer in certain 
milk products
Candy for space 
feeding 
Enriched dairy 
drink for infants
Meat replacement
Dental fi lling 
material
Mineral binding 
activity
Reference(s) [16–24] [14–18,23,24] [16–21,23,24] [16–18,23,24] [21–26] [27]
Fig. 2 Production of whey protein-enriched products.
Table 3 Characteristics of sweet and acid whey
Type of whey Sweet whey Acid whey
Total solids 6.4 6.5
Water 93.6 93.5
Fat 0.05 0.04
True protein 0.55 0.55
Non-protein nitrogen 0.18 0.18
Lactose 4.8 4.9
Mineral/ash content 0.5 0.8
pH Minimum: pH 5.6 Maximum: pH 5.1
Source: Data adapted from Nielsen.[28]
Table 4 Individual whey proteins and their nutritional and pharmaceutical applications
Fractionated 
whey α-La β-Lg
Lactoperoxidase 
(LPO)
Lactoferrin 
(LF)
Immunoglobulins 
(Igs)
Glycomacropeptide 
(GMP)
Applications Infant formula Cold sterilization of milk 
(antibacterial activity)
Milk-based infant 
formulae (iron 
absorption and 
protection against 
enteric infection in 
neonates)
Formulae for 
preterm infants
Nutrition of patients 
with phenylketonuria 
(contains no Phe, 
Tyr, Trp, Lys, or Cys 
residues)
Reference(s) [32–41] [35,42–44] [46,47] [48] [48–50] [50,51]
Whey-derived products include whey protein powder, 
whey protein concentrate (WPC), whey protein isolate (WPI), 
and individual whey proteins like β-Lg or α-Lg (Fig. 2).
Whole whey powders containing less than 15% protein 
are produced by concentrating whey by evaporation alone or 
in combination with reverse osmosis followed by spray dry-
ing. Demineralized and demineralized–delactosed whey 
powders containing 15–35% protein are produced by reverse 
osmosis, electrodialysis or ion-exchange and/or lactose crys-
tallization to reduce the mineral and/or lactose whey contents.
WPCs are produced under mild conditions of pH and 
temperature by ultrafi ltration of whey. They can be in liq-
uid or dry form and have a protein content that typically 
ranges from 34% to 85%. When the protein concentration 
 
 
4760 Milk Proteins
M
icrogels—
M
ilk Proteins
Whey protein fractionation processes are mainly based 
on membrane separation and chromatographic techniques. 
Table 5 summarizes the current food and pharmaceutical 
applications of some individual whey proteins.
Casein–whey protein coprecipitates
Whey proteins can be coprecipitated with CN by fi rst heat-
ing milk, at its natural pH, to temperatures that denature the 
whey proteins and induce their complexation with CN, fol-
lowed by precipitation of the milk protein complex by acid-
ifi cation to pH 4.6 or by addition of CaCl2 combined with 
variable levels of acidifi cation. Such products, referred to as 
high-, medium-, or low-calcium CN–whey protein copre-
cipitates based on the calcium content, generally exhibit 
poor solubility. Insoluble coprecipitates can be dissolved in 
sodium tripolyphosphate and sodium hydroxide.[54]
Coprecipitates are used as carbohydrate-free and low-
lactose infant food. High-calcium coprecipitate is used as a 
cake mix for diabetics and soluble low-calcium coprecipi-
tate in nutrition, for imitation rice.
BIOLOGICAL EFFECTS OF MILK PROTEINS
General Health Benefits
Proteins have biological activities associated with the intact 
proteins themselves or with amino acid sequences within 
the proteins. These activities can be triggered by the intact 
protein on hydrolysis by proteolytic enzymes, microbial 
proteolytic activity, or by common food processing treat-
ments (heating and acid/alkaline conditions).
The fi rst food-derived bioactive peptide was identifi ed in 
1950 when Mellander reported that milk protein CN and its 
phosphorylated peptides enhanced vitamin D-independent 
bone calcifi cation in rachitic infants.[55] Biologically active 
peptides can be generated in vivo during gastrointestinal 
digestion of milk protein or released in vitro on hydrolysis 
of milk proteins; these biologically active peptides include 
angiotensin-converting enzymes (ACE) inhibitors, anti-
thrombotic, opioid agonists, opioid antagonists, antimicro-
bial, immunomodulatory and anxiolytic peptides, and CN 
phosphopeptides. Some CN derivatives have antimicrobial 
effect (Table 6), ameliorate intestinal calcium uptake, and 
also show  proinfl ammatory and immunomodulatory prop-
erties. A study exposed that αS1-CN may be, as well, a 
 leukocyte-derived peptide and possesses immunomodula-
tory properties.[58] Caseins have shown a protective effect in 
experimental bacteremia by stimulating myelopoiesis. Their 
hydrolyzates are protective in diabetic animals, decrease the 
tumor growth, and weaken colicky symptoms in infants. 
Casein-derived peptides confi rm some antihypertensive 
effects. Glycomacropeptide, derived from κ-CN, exhibits 
antibacterial and antithrombotic activities. Starter and 
 non-starter bacteria, predominantly lactic acid bacteria, are 
generally highly proteolytic and are capable of generat-
ing bioactive peptides from milk proteins during the 
Table 6 Antimicrobial activity of milk casein derivatives
Antimicrobial 
compound Microorganism Reference(s)
Lactenin (generated 
following the 
treatment of 
milk with rennin)
Streptococci [56,57]
Caseicin A and 
B peptides
Cronobacter sakazakii
Escherichia coli
Casocidin I Escherichia coli
Staphylococcus carnosus
Cronobacter sakazakii
Listeria innocua
Streptococcus mutans
Isracidin Staphylococcus aureus
Listeria monocytogenes
Candida albicans
Table 5 Whey protein-enriched products and their nutritional and pharmaceutical uses
Whey product
Whey protein 
concentrates (WPC)
Whey protein 
isolates (WPI)
Whey protein 
hydrolyzate (WPH)
Delactosed 
whey powder
Demineralized 
whey powder
Demineralized–
delactosed whey 
powder
Protein 
concentration
35–85% 90–95% 94% ~30% 15–35% 15–35%
Applications Geriatric/hospital/ 
liquid diets
Infant formulae
Pharmaceutical 
formulae
Nutritional 
proteinbar/
beverages
Pharmaceutical 
formulae
Hypoallergenic 
infant formulae
Pharmaceutical 
formulae
Dietary supplementation
Reference(s) [33,52] [53] [53] [33] [33] [33]
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 fermentation of milk-based products. ACE-inhibitory, 
immunomodulatory, anti-oxidative, antimutagenic, and opi-
oid activities have all been identifi ed in fermented milk and/
or cheeses.[59]
α-Lactalbumin revealed antiviral, antitumor, and anti-
stress properties. Diets rich in α-La were anxiolytic, lowered 
blood pressure in rats, led to a superior weight gain in mal-
nourished youngsters and prevented diarrhea.[60] Lactoferrin 
(LF) was the fi rst iron-binding protein described in milk by 
Johansson in 1960.[61] It exhibits antibacterial (specifi cally 
microbiostatic properties against Escherichia coli),[61,62] anti-
fungal, antiviral, antiparasitic, and antitumor activities. It is 
protective with respect to intestinal epithelium, stimulates 
bone growth, and accelerates recovery of the immune sys-
tem function in immunocompromised animals. LF exhibits 
a variety of effects on the host immune system, ranging from 
inhibition of infl ammation to promotion of both innate and 
adaptive immune responses.[63] Although the mechanisms 
underlying these LF immunomodulatory properties have not 
been fully elucidated yet, evidence indicates that the capac-
ity of this molecule to directly interact with antigen present-
ing cells (APC), i.e. monocytes/macrophages and dendritic 
cells, may play a critical role. At the cellular level, LF modu-
lates important aspects of APC biology, including migration 
and cell activation, whereas at the molecular level it affects 
expression of soluble immune mediators, such as cytokines, 
chemokines, and other effector molecules, thus contributing 
to the regulation of infl ammation and immunity.[64,65] Addi-
tionally, LF-derived peptides inhibit ACE activity in vitro 
and reduce systolic blood pressure in hypertensive rat and 
displayed potential as orally effective antihypertensive com-
pounds.[66] Other milk proteins also have potential therapeu-
tic properties: proline-rich polypeptide exhibits a variety of 
immunotropic functions, as well as promotion of T-cell 
maturation and inhibition of autoimmune disorders. It was 
shown to increase or stabilize the instrumental activity of 
daily living status in patients with Alzheimer’s  disease; lyso-
zyme is effective in treatment of periodontitis and preven-
tion of tooth decay; and, fi nally, lactoperoxidase shows 
antibacterial properties.[67]
Cancer Protection
Animal and cell culture studies suggest that milk proteins, 
especially whey, have anticarcinogenic properties. This 
activity seems to be linked to components rich in sulfur 
amino acids, cysteine and methionine, and holding the 
γ-glutamylcysteine residue, which makes cysteine (and 
methionine, in times of cysteine defi ciency) readily bio-
available for the synthesis of glutathione, a strong xenobi-
otic deactivating and antineoplastic agent.[68] Binding of 
iron by LF may make this potential pro-carcinogen unavail-
able for intestinal damage, whereas the vitamin B-binding 
proteins make their vitamins, potential anticancer agents, 
more bioavailable and keep them from use by intestinal 
microorganisms.[68]
BIOMEDICAL APPLICATIONS
Milk proteins are widely used in the food industry for their 
nutritional and functional properties. The fact that milk pro-
teins are inexpensive, readily available, natural, and non-toxic 
makes them interesting for potential biomedical applications. 
Temporary replacement implants, tissue-engineering scaf-
folding, membranes for promoting wound healing, and drug 
delivery carriers are the most promising target applications.
Drug Delivery
Milk proteins are natural vehicles for bioactives. Several of 
their structural and physico-chemical properties facilitate 
their functionality in delivery systems: excellent surface 
and self-assembly properties, binding of ions and small 
molecules, pH-responsive gel, brilliant gelation properties, 
suitable for programmable release, conjugates with syner-
gistic combinations of properties, interactions with other 
macromolecules to form complexes, crucial for protecting 
sensitive payload, swelling performance, biocompatibility 
and biodegradability, many shielding abilities, assisting to 
control the bioaccessibility of the bioactive, and stimulate 
its bioavailability.[69]
The versatility and potential of CNs and whey proteins 
in drug delivery applications are well patented in the 
research work summarized in Tables 7 and 8.
Tissue Regeneration and Wound Healing
Recent advances in tissue engineering have focused on 
fi nding more biocompatible, non-toxic materials to imitate 
natural tissue components.[100]
Besides biocompatibility and biodegradability, milk 
proteins may also present some bioactivity. For example, 
the uniqueness of LF as a skeletal regenerative molecule 
lies in its ability to favorably modulate the responses of the 
various cell types involved in musculoskeletal regeneration. 
Human LF is also known to promote neovascularization. 
This molecule reveals pleiotropic functions, encourages the 
proliferation and differentiation of osteoblast cells, and bars 
osteoclast-mediated bone resorption.[101]
In Table 9 are summarized the main reported studies 
using both CN and whey proteins in tissue engineering and 
wound healing.
CONCLUSION
Milk contains a mixture of proteins, each having unique 
attributes for nutritional, biological, and food applications. 
The major proteins present in milk include the CNs, β-Lg, 
and α-La. Minor but also important proteins are LF and 
lactoperoxidase. This entry presented an overview of man-
ufacturing processes, biological activities, and applications 
in the food and nutraceutical fi elds.
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Table 7 Drug delivery systems based on caseins
Vehicle Drug(s) Application Reference(s)
Film coating Diltiazem Oral controlled drug release [70]
Composite Phenytoin Oral improvement of release [71]
Ibuprofen Oral, N.A. [72]
Diclofenac Oral controlled drug release [73]
Hydrogel Vitamin B12 Oral controlled drug release [74]
(micro)beads Loratadine Oral controlled drug release [75]
Diethylstilboestrol Parenteral controlled drug release [76]
Microparticles Methotrexate N.A., controlled drug release [77]
Acetaminophen N.A., controlled drug release [78]
β-Lactoglobulin Oral controlled drug release [79]
5-Fluorouracil Implantation, site-specifi c (tumor) 
and controlled drug release
[80]
Microspheres Levonorgestrel Parenteral controlled drug release [81]
Microcapsules Acetaminophen Oral controlled drug release [82]
Nanocarriers Vitamin D2 Oral controlled drug release [83]
Curcumin Oral site-specifi c (tumor) drug release [84]
Mitoxantrone Oral site-specifi c (tumor) drug release [85]
Celecoxib + 
Budesonide
Oral site-specifi c (intestine) 
controlled drug release
[86]
Mitoxantrone Oral drug release [85]
Paclitaxel
Vinblastine
Oral drug release [87]
Table 8 Drug delivery systems based on whey proteins
Protein type Vehicle Drug/bioactive Application Reference(s)
WPC Hydrogel Caffeine Controlled delivery [88]
WPI Alginate/whey microparticles Insulin Improvement of oral bioavailability [89]
Alginate/whey protein beads Theophylline Controlled drug delivery [90]
Alginate/whey protein microspheres Ribofl avin Controlled drug delivery [91]
Beads Retinol Protection against oxidation and 
sustained delivery
[92]
Aerogel Ketoprofen Controlled diffusive drug delivery [93]
Hydrogel Anthocyanin-rich bilberry 
extract
Improved stability and controlled 
delivery of anthocyanins
[94]
O/W/O double emulsions Flumethrin® Sustained release of hydrophobic drugs 
for topical uses
[95]
β-La Nanoparticles Caffeine Controlled delivery [96]
Nanocomplexes  EGCG Protection against oxidative 
degradation and sustained release
[97]
Succinylated 
β-La
Tablet Ribofl avin Controlled drug delivery [98]
Tablet Probiotic microorganism Intestinal delivery [99]
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Recently, milk proteins have received considerable 
interest for drug delivery and tissue engineering applica-
tions. However, compared to other biopolymers, their use 
is still limited, especially in the fi eld of tissue engineering, 
and thus, further investigation is required.
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